• Aurobindo's first quarter results released. Posts consolidated Net profit of Rs 415.4 Crores.
   

Global leadership position In Anti-infectives

Among the largest ' Vertically Integrated ' pharmaceutical companies in India, Aurobindo has robust product portfolio spread over major product areas encompassing CVS, CNS, Anti-Retroviral, Antibiotics, Gastroenterologicals, Anti-Diabetics and Anti-Allergic with approved manufacturing facilities by USFDA, UKMHRA, WHO, MCC-SA, ANVISA-Brazil for both APIs & Formulations

Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry.

Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others...

More

Founder's Message

Founder
Mr. P.V. Ramaprasad Reddy

To become Asia's leading and one among the top 15 generic Pharma companies in the world, by 2015.

More

Chairman's Message

Chairman
Mr. K Ragunathan

The pharmaceutical industry needs a high level of consistency in terms of quality of drugs and medicines....

More